Related Experiment Videos

Nicorandil decreases cardiac events during and after noncardiac surgery

Satoshi Kashimoto1, Makoto Seki, Toshihiko Ishiguro

  • 1Department of Anesthesiology, Faculty of Medicine, University of Yamanashi, Tamaho, Yamanashi 409-3898, and Department of Anesthesia, Cancer Institute Hospital, Tokyo, Japan. satoshik@yamanashi.ac.jp

Journal of Clinical Anesthesia
|February 27, 2007
PubMed

Insights

Nicorandil significantly reduced cardiac events in intermediate-risk patients undergoing noncardiac surgery. This medication proved effective both during and after the operative procedure, enhancing patient safety.

Area of Science:

  • Cardiology
  • Anesthesiology
  • Pharmacology

Background:

  • Noncardiac surgery poses risks for cardiac events in intermediate-risk patients.
  • Identifying effective interventions to mitigate perioperative cardiac complications is crucial.

Purpose of the Study:

  • To evaluate the efficacy of nicorandil in preventing cardiac events during and after intermediate-risk noncardiac surgery.

Main Methods:

  • A multicenter study involving 13 hospitals in Japan.
  • Intermediate-risk patients were identified based on factors like angina, prior myocardial infarction, heart failure, diabetes, and abnormal ECG.
  • Nicorandil was administered during surgery.

Main Results:

  • Cardiac events occurred less frequently in the nicorandil group compared to the standard care group.
  • During surgery, the odds ratio for cardiac events was 0.15 (P=0.02).
  • After surgery, the odds ratio for cardiac events was 0.24 (P=0.04).

Conclusions:

  • Nicorandil effectively reduces the frequency of cardiac events in patients undergoing noncardiac surgery.
  • The protective effect of nicorandil was observed both intraoperatively and postoperatively.
Abstract

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...